Patent intelligence · US
US 11149253
Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application
Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogra…
Patent details — US 11149253
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 19, 2021
- Expiration
- Oct 14, 2041
- Claims
- 19
- CPC classes
- A61K, A61K35/12, A61P, A61P35/00
Quick answer
US 11149253 (Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application) is held by INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA. Status: granted. Granted Oct 19, 2021. Expires Oct 14, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K35/12, A61P, A61P35/00
More from INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA
Related pharmaceutical patents in our USPTO index.
-
US 12427137
Method for reducing methane production in animal stomach
granted -
US 12421269
SGLT2/DPP4 inhibitor and application thereof
granted -
US 12403167
Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament
granted -
US 12397034
Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons
granted -
US 12389931
Oyster peptide with effect of improving sexual function and preparation method thereof
granted -
US 12383535
Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor
granted -
US 12378241
Pyridine derivative as FGFR and VEGFR dual inhibitors
granted -
US 12371434
MLL1 inhibitors and anti-cancer agents
granted
Frequently asked questions
What is US patent 11149253?
US 11149253 (Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application) is held by INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA. Status: granted. Granted Oct 19, 2021. Expires Oct 14, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11149253?
INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 335 pharmaceutical patents for this assignee.
When does US 11149253 expire?
Our index shows an expiration date of Oct 14, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.